All Dark Blue Therapeutics articles
-
News
Amgen acquires UK cancer biotech Dark Blue Therapeutics for $840m
Gains access to the company’s small molecule-targeted protein degraders to expand its oncology pipeline.
Gains access to the company’s small molecule-targeted protein degraders to expand its oncology pipeline.